ZA201504902B - Bcl-2bcl-xl inhibitors and therapeutic methods using the same - Google Patents
Bcl-2bcl-xl inhibitors and therapeutic methods using the sameInfo
- Publication number
- ZA201504902B ZA201504902B ZA2015/04902A ZA201504902A ZA201504902B ZA 201504902 B ZA201504902 B ZA 201504902B ZA 2015/04902 A ZA2015/04902 A ZA 2015/04902A ZA 201504902 A ZA201504902 A ZA 201504902A ZA 201504902 B ZA201504902 B ZA 201504902B
- Authority
- ZA
- South Africa
- Prior art keywords
- 2bcl
- bcl
- inhibitors
- same
- therapeutic methods
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361753066P | 2013-01-16 | 2013-01-16 | |
| PCT/US2014/011571 WO2014113413A1 (en) | 2013-01-16 | 2014-01-15 | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201504902B true ZA201504902B (en) | 2016-07-27 |
Family
ID=51165292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2015/04902A ZA201504902B (en) | 2013-01-16 | 2015-07-08 | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9096625B2 (enExample) |
| EP (2) | EP2945940B1 (enExample) |
| JP (1) | JP6347793B2 (enExample) |
| KR (2) | KR102318204B1 (enExample) |
| CN (3) | CN110302205B (enExample) |
| AU (1) | AU2014207716B2 (enExample) |
| CA (1) | CA2897055C (enExample) |
| ES (1) | ES2819232T3 (enExample) |
| HK (1) | HK1219734A1 (enExample) |
| NZ (1) | NZ709635A (enExample) |
| SG (1) | SG11201505525UA (enExample) |
| WO (1) | WO2014113413A1 (enExample) |
| ZA (1) | ZA201504902B (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102318204B1 (ko) * | 2013-01-16 | 2021-10-26 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법 |
| EP3099380B1 (en) | 2014-01-28 | 2021-08-11 | Buck Institute for Research on Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| EP3139942B1 (en) | 2014-05-05 | 2019-12-18 | Bioventures, Llc | COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS |
| JP2017522388A (ja) | 2014-07-22 | 2017-08-10 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ | 老化細胞を選択的に枯渇させるための組成物及び方法 |
| AU2016215035A1 (en) * | 2015-02-06 | 2017-09-28 | Buck Institute For Research On Aging | Compounds and uses in treatment of senescence-associated conditions |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| WO2017101851A1 (en) * | 2015-12-18 | 2017-06-22 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
| WO2017172826A1 (en) | 2016-03-28 | 2017-10-05 | Presage Biosciences, Inc. | Pharmaceutical combinations for the treatment of cancer |
| JP6936498B2 (ja) * | 2016-04-21 | 2021-09-15 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ | 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用 |
| CN106177955B (zh) * | 2016-08-18 | 2018-03-16 | 广州威溶特医药科技有限公司 | Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| WO2018098534A1 (en) * | 2016-12-02 | 2018-06-07 | Garvan Institute Of Medical Research | Methods of treating cancer and reagents thereof |
| US20200354336A9 (en) * | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
| WO2019033122A1 (en) * | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
| WO2019033119A1 (en) * | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
| EP3548504B1 (en) | 2017-12-30 | 2021-07-21 | Unity Biotechnology, Inc. | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
| CA3087262A1 (en) | 2018-01-10 | 2019-07-18 | Recurium Ip Holdings, Llc | Benzamide compounds |
| ES3041854T3 (en) * | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| MX2020011495A (es) | 2018-04-29 | 2021-01-15 | Beigene Ltd | Inhibidores de bcl-2. |
| US10738042B2 (en) | 2018-04-30 | 2020-08-11 | Unity Biotechnology, Inc. | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| CA3056878C (en) | 2018-04-30 | 2021-03-30 | Unity Biotechnology | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2019213160A1 (en) | 2018-04-30 | 2019-11-07 | Unity Biotechnology | Acyl phosphonamidates and acyl benzylamines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2019221755A1 (en) | 2018-05-18 | 2019-11-21 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| EP3672595B1 (en) | 2018-07-31 | 2021-07-21 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| AU2019315550B2 (en) * | 2018-07-31 | 2021-07-01 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof |
| US11491168B2 (en) | 2018-07-31 | 2022-11-08 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof |
| EP3672594B1 (en) | 2018-07-31 | 2021-09-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| CN110772640B (zh) | 2018-07-31 | 2023-02-03 | 苏州亚盛药业有限公司 | Bcl-2抑制剂与利妥昔单抗和/或苯达莫司汀或与CHOP联合的协同抗肿瘤作用 |
| CN114522167A (zh) | 2018-07-31 | 2022-05-24 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| WO2020041405A1 (en) | 2018-08-22 | 2020-02-27 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| US11872237B2 (en) * | 2018-12-28 | 2024-01-16 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition and preparation method thereof |
| TWI731540B (zh) * | 2019-01-04 | 2021-06-21 | 大陸商蘇州亞盛藥業有限公司 | 製備磺胺類藥物的方法 |
| WO2020140956A1 (en) * | 2019-01-04 | 2020-07-09 | Ascentage Pharma (Suzhou) Co., Ltd. | Process for preparing sulfonamide compounds |
| TWI770503B (zh) * | 2019-05-13 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物 |
| CN112168830B (zh) * | 2019-07-02 | 2022-01-25 | 苏州亚盛药业有限公司 | 一种含有mTOR抑制剂的药物组合及其应用 |
| CN112294966B (zh) * | 2019-07-31 | 2021-12-17 | 苏州亚盛药业有限公司 | Bcl-2/Bcl-xL抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途 |
| US20220372042A1 (en) | 2019-10-03 | 2022-11-24 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| CN112707900B (zh) * | 2019-10-24 | 2022-06-10 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| CN112852959B (zh) * | 2019-11-27 | 2026-02-06 | 苏州亚盛药业有限公司 | 用于预测靶向细胞凋亡途径的化合物的抗癌功效的方法和组合物 |
| US12514863B2 (en) | 2019-12-04 | 2026-01-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical combination and use thereof |
| WO2021119439A1 (en) * | 2019-12-11 | 2021-06-17 | The Regents Of The University Of Michigan | Compositions and methods for systemic delivery of bcl-2 and bcl-xl antagonists |
| CN113350281B (zh) * | 2020-03-02 | 2023-08-15 | 苏州亚盛药业有限公司 | 载药聚合物胶束及其制剂和制备方法 |
| WO2021204060A1 (en) * | 2020-04-10 | 2021-10-14 | Ascentage Pharma (Suzhou) Co., Ltd. | Combinations of bcl-2/bcl-xl inhibitors and related uses |
| KR20230002419A (ko) | 2020-04-15 | 2023-01-05 | 베이진 엘티디 | Bcl-2 억제제 |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| EP4175644A1 (en) | 2020-07-06 | 2023-05-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| US12528832B2 (en) | 2020-07-13 | 2026-01-20 | Ascentage Pharma (Suzhou) Co., Ltd. | Crystalline or amorphous form of Bcl-2/Bcl-xL inhibitor compound or its salts |
| WO2022022706A1 (en) * | 2020-07-31 | 2022-02-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Compositions and methods for treating lung diseases |
| CN117062808A (zh) * | 2020-11-10 | 2023-11-14 | 联合生物科技公司 | Bcl的结晶固体葡甲胺盐抑制剂及其制备和使用方法 |
| WO2022111647A1 (en) * | 2020-11-27 | 2022-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | Formulation combination containing freeze-dried formulation and reconstituted solvent, preparation method and application thereof |
| US12454674B2 (en) | 2020-12-04 | 2025-10-28 | University Of Notre Dame Du Lac | Method of encapsulating single cells utilizing an alternating current electrospray |
| WO2023011488A1 (zh) | 2021-08-02 | 2023-02-09 | 苏州亚盛药业有限公司 | 一种药物组合及其用途 |
| TW202415653A (zh) * | 2022-08-02 | 2024-04-16 | 大陸商北京星奇原生物科技有限公司 | Ｂｃｌ－ｘｌ降解化合物 |
| TW202415647A (zh) * | 2022-09-06 | 2024-04-16 | 大陸商西藏海思科製藥有限公司 | 抑制Bcl-2或Bcl-xL的化合物及其在醫藥上的應用 |
| WO2024245312A1 (en) * | 2023-05-30 | 2024-12-05 | Ascentage Pharma (Suzhou) Co., Ltd. | Bcl-2/bcl-xl protein degrader and use thereof |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432304B2 (en) | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| CA2577752A1 (en) | 2004-08-20 | 2006-03-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| PT1888550E (pt) | 2005-05-12 | 2014-09-03 | Abbvie Bahamas Ltd | Promotores de apoptose |
| WO2007061923A2 (en) | 2005-11-18 | 2007-05-31 | Takeda San Diego, Inc. | Glucokinase activators |
| EP2061560A2 (en) * | 2006-09-05 | 2009-05-27 | Abbott Laboratories | Bcl inhibitors for treating platelet excess |
| AU2009273197B2 (en) | 2008-07-24 | 2014-01-16 | Nerviano Medical Sciences S.R.L. | 3,4-diarylpyrazoles as protein kinase inhibitors |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| US8691184B2 (en) * | 2011-01-25 | 2014-04-08 | The Regents Of The University Of Michigan | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same |
| KR102318204B1 (ko) * | 2013-01-16 | 2021-10-26 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법 |
-
2014
- 2014-01-15 KR KR1020207037597A patent/KR102318204B1/ko active Active
- 2014-01-15 US US14/155,809 patent/US9096625B2/en active Active
- 2014-01-15 AU AU2014207716A patent/AU2014207716B2/en active Active
- 2014-01-15 NZ NZ70963514A patent/NZ709635A/en unknown
- 2014-01-15 EP EP14741180.5A patent/EP2945940B1/en active Active
- 2014-01-15 ES ES14741180T patent/ES2819232T3/es active Active
- 2014-01-15 EP EP20163914.3A patent/EP3689886A1/en not_active Withdrawn
- 2014-01-15 SG SG11201505525UA patent/SG11201505525UA/en unknown
- 2014-01-15 CA CA2897055A patent/CA2897055C/en active Active
- 2014-01-15 HK HK16107756.1A patent/HK1219734A1/zh unknown
- 2014-01-15 WO PCT/US2014/011571 patent/WO2014113413A1/en not_active Ceased
- 2014-01-15 JP JP2015553788A patent/JP6347793B2/ja active Active
- 2014-01-15 CN CN201910634742.2A patent/CN110302205B/zh active Active
- 2014-01-15 CN CN201910634723.XA patent/CN110305162A/zh active Pending
- 2014-01-15 KR KR1020157021823A patent/KR102210316B1/ko active Active
- 2014-01-15 CN CN201480015733.0A patent/CN105246882A/zh active Pending
-
2015
- 2015-07-08 ZA ZA2015/04902A patent/ZA201504902B/en unknown
- 2015-08-03 US US14/816,191 patent/US9403856B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201505525UA (en) | 2015-08-28 |
| JP2016506916A (ja) | 2016-03-07 |
| US9403856B2 (en) | 2016-08-02 |
| CA2897055A1 (en) | 2014-07-24 |
| US9096625B2 (en) | 2015-08-04 |
| EP2945940A4 (en) | 2016-07-06 |
| US20140199234A1 (en) | 2014-07-17 |
| US20150336994A1 (en) | 2015-11-26 |
| WO2014113413A1 (en) | 2014-07-24 |
| KR20150104631A (ko) | 2015-09-15 |
| EP2945940B1 (en) | 2020-07-15 |
| JP6347793B2 (ja) | 2018-06-27 |
| CN110305162A (zh) | 2019-10-08 |
| KR102210316B1 (ko) | 2021-01-29 |
| CA2897055C (en) | 2021-04-20 |
| KR20210002126A (ko) | 2021-01-06 |
| AU2014207716B2 (en) | 2017-07-27 |
| CN110302205B (zh) | 2020-06-09 |
| ES2819232T3 (es) | 2021-04-15 |
| CN110302205A (zh) | 2019-10-08 |
| EP3689886A1 (en) | 2020-08-05 |
| HK1219734A1 (zh) | 2017-04-13 |
| CN105246882A (zh) | 2016-01-13 |
| KR102318204B1 (ko) | 2021-10-26 |
| EP2945940A1 (en) | 2015-11-25 |
| NZ709635A (en) | 2019-10-25 |
| AU2014207716A1 (en) | 2015-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291723A (en) | Methods and devices for skin tightening | |
| ZA201504902B (en) | Bcl-2bcl-xl inhibitors and therapeutic methods using the same | |
| IL269462B (en) | mdm2 inhibitors and therapeutic methods using them | |
| IL267681A (en) | Selective grp94 inhibitors and their uses | |
| IL286759A (en) | Therapeutic methods and preparations | |
| GB201320729D0 (en) | Therapeutic compounds and their use | |
| IL241370A0 (en) | Carm1 inhibitors and their uses | |
| PL3063275T3 (pl) | Terapeutyczne fuzje nukleaza-albumina i sposoby | |
| GB201306633D0 (en) | Biaising circuitry and method thereof | |
| GB201301626D0 (en) | Composition comprising 15-OHEPA and methods of using the same | |
| GB201311361D0 (en) | Compounds and their therapeutic use | |
| IL244214A0 (en) | Thienopiperidine derivative and its use | |
| GB201308736D0 (en) | Compounds and their therapeutic use | |
| PT3024825T (pt) | Imidazolecarboxamidas e seu uso como inibidores da faah | |
| GB201308753D0 (en) | Compounds and their use in therapy | |
| EP3073825A4 (en) | Inhibitors of ercc1-xpf and methods of using the same | |
| GB201310502D0 (en) | Device and methods | |
| GB201308217D0 (en) | Compounds and their use in therapy | |
| EP3071207A4 (en) | Libido-enhancing therapeutic and use | |
| GB201319255D0 (en) | Therapeutic compositions and methods | |
| GB201317804D0 (en) | Therapeutic compounds and their use | |
| GB201316173D0 (en) | Compounds and their therapeutic use | |
| GB201307677D0 (en) | Compounds and their therapeutic use | |
| IL242818B (en) | Il-1beta-il-1ra chimera and methods of using the same | |
| SG10201707533TA (en) | Phototherapy devices and methods |